Skeletal Muscle and Plasma Lipidomic Signatures of Insulin Resistance and Overweight/Obesity in Humans

Katherine T. Tonks1,2,3*, Adelle CF Coster1,4*, Michael J. Christopher5*, Rima Chaudhuri6, Aimin Xu7, Johann Gagnon-Bartsch8, Donald J. Chisholm1,2, David E. James6, Peter J. Meikle5, Jerry R. Greenfield2,3, and Dorit Samocha-Bonet1,2

Objective: Alterations in lipids in muscle and plasma have been documented in insulin-resistant people with obesity. Whether these lipid alterations are a reflection of insulin resistance or obesity remains unclear.

Methods: Nondiabetic sedentary individuals not treated with lipid-lowering medications were studied (n = 51). Subjects with body mass index (BMI) > 25 kg/m² (n = 28) were stratified based on median glucose infusion rate during a hyperinsulminemic-euglycemic clamp into insulin-sensitive and insulin-resistant groups (above and below median, obesity/insulin-sensitive and obesity/insulin-resistant, respectively). Lean individuals (n = 23) served as a reference group. Lipidomics was performed in muscle and plasma by liquid chromatography electrospray ionization-tandem mass spectrometry. Pathway analysis of gene array in muscle was performed in a subset (n = 35).

Results: In muscle, insulin resistance was characterized by higher levels of C18:0 sphingolipids, while in plasma, higher levels of diacylglycerol and cholesterol ester, and lower levels of lysoalkylphosphatidylcholine, indicated insulin resistance, irrespective of overweight/obesity. The sphingolipid metabolism gene pathway was upregulated in muscle in insulin resistance independent of obesity. An overweight/obesity lipidomic signature was only apparent in plasma, predominated by higher triacylglycerol and lower plasmalogen species.

Conclusions: Muscle C18:0 sphingolipids may play a role in insulin resistance independent of excess adiposity.

Introduction

Overweight and obesity are major risk factors of type 2 diabetes, but some people with obesity may be relatively protected from developing type 2 diabetes. The key determinant of “metabolic health” in obesity is insulin sensitivity (1). However, the majority of the population with obesity is insulin-resistant. Numerous factors have been implicated in the etiology of insulin resistance in obesity, including increased visceral adiposity, liver lipids, impaired adipose tissue expansion, and adipose tissue inflammation (1).

Alterations in skeletal muscle lipids have received much attention in the study of insulin resistance. Most studies have found increased triacylglycerol (TG) in skeletal muscle in sedentary insulin-resistant individuals, but increased TG in muscle in insulin-sensitive women and athletes suggests TG are metabolically inactive (2). Conversely,
diacylglycerol (DG) and ceramide (Cer) have been implicated in insulin resistance in animal models. Cer is the “hub” lipid in sphingolipid metabolism, serving as a precursor for sphingomyelin (SM) and the higher order sphingolipids monohexosylceramide (MHC/HexCer), dihexosylceramide (DHC/Hex2Cer), trihexosylceramide (THC/Hex3Cer), and GM3 ganglioside (GM3) and generated de novo from dihydroceramide (dhCer) or breakdown of SM (2,3). Studies in various animal models, including from our group, have identified Cer(d18:1/16:0) and/or Cer(d18:1/18:0) in liver (4-6) and skeletal muscle (5) as potential players in insulin resistance. In humans, the contribution of Cer and DG to insulin resistance is still debated. Muscle DG(18:0_20:4), DG(16:0_16:0), and DG(18:0_18:0) were increased in type 2 diabetes compared with nondiabetic individuals with similar obesity and lean athletes (7), and muscle Cer(d18:1/16:0) and Cer(d18:1/18:0) were increased in insulin-resistant versus insulin-sensitive women with obesity (8). However, others have found neither DG (2,5,13) nor Cer (9,10) alterations in muscle in insulin-resistant individuals.

Circulating lipid species likely represent a readout of tissues, particularly liver (11), and possibly also reflect muscle lipid composition. Our studies have revealed that the plasma lipidome signature explained much of the variability in glucose homeostasis in large cohorts (12), and specific lipids emerged as potential biomarkers of glucose intolerance and type 2 diabetes, including Cer(d18:1/18:0) and its dhCer precursor (13).

While large cohort studies are powerful in identifying potential lipid contributors to metabolic disease, a major limitation is the inability to distinguish between lipid correlates of insulin resistance and obesity. Here we report a comprehensive lipidomic analysis of skeletal muscle and plasma in adiposity-matched insulin-resistant and insulin-sensitive individuals compared to a lean insulin-sensitive group. We use hyperinsulinemic-euglycemic clamps to define insulin-sensitive compared to a lean insulin-sensitive group. In this study design enabled dissection of tissue lipids and lipid-related pathways potentially involved in insulin resistance from those associated with obesity per se in humans.

Methods
Participants
Eighty-one individuals aged 40-70 years were included in the original study (14). For lipidomic analyses, type 2 diabetes patients (n = 21) and individuals treated with lipid-lowering medications (statins [n = 8] or ezetimibe [n = 1]) were excluded; therefore, findings for n = 51 are reported. Inclusion and exclusion criteria were reported previously (14). The study was approved by the Human Research and Ethics Committee, St. Vincent’s Hospital, Sydney, and participants provided informed written consent before study commencement.

Definition of insulin-sensitive and insulin-resistant individuals with overweight/obesity
Individuals with body mass index (BMI) > 25 kg/m² (n = 28) were stratified based on median glucose infusion rate (GIR) normalized to fat-free mass (FFM) with separate cutoffs for men and women (52 and 93 μmol/min/kgFFM, respectively), into insulin-sensitive (OIS, >median, n = 14) and insulin-resistant (OIR, <median, n = 14) groups.

Metabolic assessment
Hyperinsulinemic (80 mU/m²/min)-euglycemic (5 mmol/L) 2.5-h clamps with indirect calorimetry (ParvoMedics Inc. UT, US) at baseline and clamp steady state to determine resting and insulin-stimulated respiratory quotient (RQ) were performed, as described (14). Vastus lateralis muscle was biopsied at baseline and 30 and 145 min of the clamp, snap-frozen and stored at −80°C until analyzed (14).

Body composition and abdominal fat distribution
Dual energy X-ray absorptiometry (DXA, Lunar DPX-Lunar Radiation, Madison WI) assessed body composition. Computed tomography (CT; Philips Gemini GXL) assessed abdominal fat distribution at L2/L3 and L4/L5, and liver and spleen attenuation (14). The ratio between attenuation of liver and spleen was the indicator of liver fat.

For biochemical analysis in blood and Western blotting in muscle, refer to Supporting Information.

Plasma and muscle lipidomics
Lipid species of the following classes were measured: sphingosine (SPH), dhCer, Cer, HexCer, Hex2Cer, Hex3Cer, GM3, SM, phosphatidylcholine (PC), alkylphosphatidylcholine (PC-O), alkenylphosphatidylcholine (plasmalogen, PC-P), lysophosphatidylcholine (LPC), lysoalkylphosphatidylcholine (LPC-O), phosphatidylethanolamine (PE), alkylphosphatidylethanolamine (PE-O), alkenylphosphatidylethanolamine (plasmalogen, PE-P), lysophosphatidylethanolamine (LPE), phosphatidylserine (PS), phosphatidylglycerol (PG), cholesterol ester (CE), free cholesterol (COH), DG, and TG. For detail, refer to Supporting Information.

Gene array analysis
Two microarray-based GE experiments were conducted on muscle obtained from the original cohort (14). The first experiment used Agilent chips (14). The second was performed in another set of individuals from that cohort. The overall GE analysis comprised a subset ( Lean = 13, OIR = 11 and OIS = 11) which is the common subset of individuals where both transcriptomics and lipidomics data were available. GE profiles were obtained using both Affymetrix U133A and Agilent Whole Mouse Genome 4x44K array platforms. The relative mRNA levels for all transcripts across all subsets were studied. The raw Agilent data were pre-processed (14). GE measures obtained for ~56K transcripts using the Affymetrix U133A array platform were pre-processed using Robust Multi-array Average (RMA) method (15) in the R-programming environment.

Integrating GE data from two different microarray platforms and statistical analysis
To increase the power of data analysis, we integrated GE data obtained from Agilent and Affymetrix technologies using the Removal of Unwanted Variation (RUV-4) method (16) within R-package rUV (version 0.9.4). The probe sets in Agilent and
TABLE 1 Clinical and metabolic characteristics of the cohort

|                      | Overweight/obesity | Lean                  | Insulin-sensitive (OIS) | Insulin-resistant (OIR) | ANOVA P value |
|----------------------|--------------------|-----------------------|-------------------------|-------------------------|---------------|
| N (M/F)              | 23 (9/14)          | 14 (7/7)              | 14 (7/7)                |                         |               |
| Age (years)          | 55 ± 2             | 56 ± 3                | 58 ± 2                  | 0.6                     |               |
| BMI (kg/m²)          | 21.9 ± 0.4         | 31.0 ± 1.2**          | 33.1 ± 2.1**            | <0.001                  |               |
| Body fat (%)         | 27 ± 2             | 40 ± 2**              | 42 ± 3**                | <0.001                  |               |
| L2/L3 visceral area (cm²) | 46 ± 6          | 190 ± 42**            | 231 ± 27**              | <0.001                  |               |
| L2/L3 subcutaneous area (cm²) | 86 ± 11         | 233 ± 28**            | 248 ± 41**              | <0.001                  |               |
| L4/L5 visceral area (cm²) | 56 ± 5         | 126 ± 24**            | 177 ± 18**              | <0.001                  |               |
| L4/L5 subcutaneous area (cm²) | 151 ± 15       | 356 ± 41**            | 382 ± 52**              | <0.001                  |               |
| L4/L5 superficial subcutaneous area (cm²) | 83 ± 10       | 153 ± 23**            | 113 ± 15                | 0.01                    |               |
| L4/L5 deep subcutaneous area (cm²) | 83 ± 9        | 206 ± 33**            | 207 ± 32**              | 0.001                   |               |
| CT attenuation liver/spleen ratio | 1.35 ± 0.07 | 1.11 ± 0.12*          | 0.99 ± 0.13*            | 0.03                    |               |
| Systolic blood pressure (mm Hg) | 120 ± 3       | 125 ± 4               | 140 ± 4*                | 0.001                   |               |
| Diastolic blood pressure (mm Hg) | 73 ± 2         | 81 ± 2*               | 87 ± 2**                | <0.001                  |               |
| Glucose infusion rate (µmol/min/kg FFM) | 92 ± 5         | 90 ± 10               | 54 ± 5**##              | <0.001                  |               |
| RQBaseline           | 0.81 ± 0.01       | 0.82 ± 0.01           | 0.82 ± 0.02             | 0.6                     |               |
| Δ RQ (RQbaseline-RQclamp) | 0.13 ± 0.01   | 0.11 ± 0.01           | 0.06 ± 0.02**##         | <0.001                  |               |
| Fasting blood glucose (mmol/L) | 4.5 ± 0.1     | 4.9 ± 0.1             | 5.2 ± 0.2**             | <0.001                  |               |
| Fasting serum insulin (mU/L) | 12 ± 1        | 16 ± 2                | 22 ± 2**##              | <0.001                  |               |
| HOMA-IR              | 1.1 ± 0.1         | 2.3 ± 0.4*            | 3.6 ± 0.5**##           | <0.001                  |               |
| Fasting serum NEFA (mmol/L) | 0.37 ± 0.03   | 0.32 ± 0.04           | 0.35 ± 0.03             | 0.6                     |               |
| Fasting serum adiponectin (mg/L) | 25 ± 3        | 20 ± 3                | 16 ± 2*                 | 0.04                    |               |
| Fasting serum FABP4 (µg/L) | 15 ± 2        | 30 ± 5*               | 29 ± 5*                 | 0.01                    |               |
| Fasting serum FGF-21 (ng/L) | 93 ± 18       | 108 ± 24              | 159 ± 29                | 0.1                     |               |
| pAkt474 baselineα   | 1.0 ± 0.1         | 1.0 ± 0.2             | 1.2 ± 0.2               | 0.7                     |               |
| pAkt474 30 minα      | 6.4 ± 0.5         | 6.6 ± 0.9             | 6.5 ± 0.5               | 1.0                     |               |
| pAkt474 145 minα     | 7.8 ± 0.5         | 7.4 ± 0.8             | 7.4 ± 0.7               | 0.9                     |               |
| pAkt309 baselineα   | 1.0 ± 0.1         | 1.0 ± 0.1             | 1.3 ± 0.2               | 0.5                     |               |
| pAkt309 30 minα      | 9.3 ± 0.8         | 7.9 ± 1.1             | 7.0 ± 0.8               | 0.3                     |               |
| pAkt309 145 minα     | 12.1 ± 1.1        | 8.9 ± 1.1             | 5.7 ± 1.4**             | 0.002                   |               |
| pAS160 baselineα    | 1.0 ± 0.2         | 0.8 ± 0.1             | 0.8 ± 0.2               | 0.7                     |               |
| pAS160 30 minα       | 2.6 ± 0.4         | 1.7 ± 0.2             | 1.5 ± 0.2               | 0.07                    |               |
| pAS160 145 minα      | 2.7 ± 0.3         | 1.7 ± 0.2*            | 1.4 ± 0.6*              | 0.005                   |               |

Data are mean ± SEM.

αExpression of skeletal muscle phosphorylated proteins relative to Lean average at baseline.

BMI, body mass index; CT, computed tomography; FABP, fatty acid binding protein; FFM, fat-free mass; FGF, fibroblast growth factor; NEFA, nonesterified fatty acid; RQ, respiratory quotient.

Differences versus the Lean group **P < 0.05 and ***P < 0.01 and versus the OIS group *P < 0.05 and **P < 0.01 by one-way ANOVA and Tukey post hoc analyses.
Figure 1 Differences in concentrations of lipid species in plasma and skeletal muscle, including differences that align with (A) insulin resistance, (B) skeletal muscle concentrations of ceramide species, (C) differences between lipids in plasma and skeletal muscle that align with overweight/obesity, and (D) mixed differences. The columns in panels A, C, and D represent changes between OIR versus OIS, OIR versus Lean, and OIS versus Lean, respectively, and only lipids with significant differences between the cohorts are shown. Values in panels A, C, and D are log-fold changes of significant increases (red) and decreases (blue). Values in panel B are mean ± SEM, and statistical significance by one-way ANOVA (P < 0.05) is depicted by bars across.
Statistical analysis of clinical, metabolic, and lipidomics data

Lipidomics data were log10-transformed and differences between groups assessed using one-way ANOVA and expressed as log-fold change. Using the method outlined in a previous lipidomics report by our group (21), significance determination and control for multiple comparisons was made by assessing the distribution of the $P$ values resulting for each lipid between cohorts. If the data were random then the relationship between the $P$ values and their rank would be linear. For data in this study the relationships were clearly nonlinear for $P \leq 0.05$ (not shown), therefore, $P \leq 0.05$ was considered significant. Pearson’s correlations were calculated between lipids common in plasma and muscle, or between lipids and clinical and metabolic factors and presented as heat maps with the color indicating the pairwise linear correlation coefficient for those pairs with $P < 0.01$. Statistical analyses of clinical and metabolic data were performed using SPSS (v22) and lipidomics using Matlab R2013b (Mathworks).

Results

Clinical and metabolic characteristics of subjects

OIS and OIR had similar BMI and body fat (Table 1). L2/L3 and L4/L5 visceral and subcutaneous adipose tissue areas were higher in both OIS and OIR versus Lean, and not different between OIS and OIR ($P > 0.08$). In the L4/L5 subcutaneous area, OIS had significantly greater superficial fat versus Lean and both OIS and OIR had more deep subcutaneous fat versus Lean. Liver fat, measured as CT
attenuation of liver, was significantly higher in OIR versus Lean. OIS were not different from either Lean (P = 0.2) or OIR (P = 0.7). Systolic blood pressure was significantly higher in OIR compared with both OIS and Lean. Diastolic blood pressure was significantly higher in both obesity groups, and not different between OIS and OIR (P = 0.1). By design, insulin sensitivity measured by clamp was not different between Lean and OIS (P = 1), but was markedly reduced in OIR versus Lean and OIS (P ≤ 0.001). While baseline RQ was not different between groups, the change in RQ during hyperinsulinemia (ΔRQ), reflecting metabolic flexibility, was significantly lower in OIR versus both Lean and OIS. Fasting glucose and insulin were significantly greater in OIR versus Lean. HOMA-IR was greater in both OIR (P < 0.001) and OIS (P = 0.02) versus Lean, and also greater in OIR versus OIS (P = 0.04). Fasting NEFA were not different between groups, adiponectin was significantly lower in OIR versus Lean. FABP4 was higher in both OIR and OIS versus Lean, while FGF-21 was not different between groups.

Western blot of key insulin signaling intermediates in muscle were examined at baseline and during clamp hyperinsulinemia (Table 1). While pAkt474 expression was not different between groups at any time point (P ≥ 0.7), pAkt309 expression at 145 min was significantly lower in OIR versus Lean (P = 0.002). However, it was not different between OIR and OIS (P = 0.2) or between OIS and Lean (P = 0.2). pAS160 expression at 145 min was significantly lower in both OIR (P = 0.01) and OIS (P = 0.04) versus Lean, but was not different between OIR and OIS (P = 0.7). These findings are consistent with findings previously reported in the whole cohort (14).

Lipids specific to insulin resistance

Full list of lipids detected and within class abundance in plasma and muscle are in Supporting Information Table 1.

In plasma, insulin resistance was aligned with higher TG(16:0_16:0_16:0), DG(14:0_16:0), DG(16:0_16:0), DG(16:0_18:0), and DG(16:0_20:4), CE(16:1) and CE(20:4) and lower LPC(20:0), LPC(20:1), LPC(22:1), LPC(O-20:0) and LPC(O-22:1) (Figure 1A). Plasma lipids specific to obesity-related insulin resistance (i.e., different between OIS and OIR, but not between OIR and Lean) included DG(14:1_16:0), CE(22:4) and PC(O-35:4) (higher) and Hex2Cer(d18:1/22:0), Hex2Cer(d18:1/24:0) and LPC(22:0) (lower).

In muscle, Cer(d18:1/18:0) was the only lipid higher in insulin resistance independent of overweight/obesity. Other chain lengths Cer were not different between groups (Figure 1B). Other muscle lipid differences specific to insulin resistance in obesity included higher concentrations of C18:0 sphingolipids Hex2Cer and Hex3Cer, PC(O-34:3) and PE(O-38:4).

Lipids specific to obesity

An overweight/obesity signature was only apparent in plasma (Figure 1C), including the higher dhCer Cer(d18:0/22:0), 12 TG species, including the most abundant TG(16:0_18:1_18:1) and DG(18:0_20:4). Lipids lower in overweight/obesity included PC(O), PC(P), LPC(O-24:2), and LPE(16:0).

Lipids with mixed contributions from insulin resistance and adiposity

In many lipids in plasma and muscle, a clear insulin resistance or overweight/obesity lipid signature was not apparent, but mixed effects related to insulin resistance and adiposity were observed (Figure 1D). In plasma, a large proportion of TG, DG, and CE were higher in insulin resistance. Cer(d18:1/18:0), its precursor Cer(d18:0/18:0), and Cer(d18:1/22:0) were also higher. Conversely, many phospholipids were lower in OIR versus Lean, including a large proportion of plasma LPC(O), LPC, and PC(O) species, and PC(3-4:1). Sphingolipids that were lower in OIR versus Lean included the most and second most abundant Hex2Cer(d18:1/16:0) and Hex2Cer(d18:1/24:1), 5 of 6 Hex3Cer including the most abundant Hex3Cer(d18:1/16:0) and the two most abundant GM3 GM3(d18:1/16:0) and GM3(d18:1/24:1). In muscle, lipid species higher in OIR versus Lean included a large proportion of TG, PC(P-32:1) and PC(P-34:1), PE(O-36:4), and PE(P-36:2) and PE(P-40:4). Lower muscle lipids in OIR versus Lean included GM3(d18:1/22:0), LPC(22:6), LPE(22:6), and DG(18:2_18:2).

Relationships between glycerolipids, sphingolipids, and CE common in plasma and muscle

Of the sphingolipids detected in both plasma and muscle (n = 40), only Cer(d18:1/18:0), Hex2Cer(d18:1/24:1) and 6 SM species (of 17) correlated significantly (Figure 2). Plasma and muscle concentrations of DG(18:2_18:2) and 6 TG species also correlated.

Relationships between muscle and plasma lipids and adiposity, metabolic factors, and blood pressure

Relationships between plasma and muscle lipids with clinical and metabolic factors were assessed. In plasma (Supporting Information, Figure 1A), almost all glycerolipids correlated positively with visceral fat and many correlated with liver fat. Of the circulating factors, insulin and FGF-21 correlated positively and adiponectin inversely with many glycerolipids, but FABP4 did not correlate with any. Metabolic flexibility (ΔRQ) correlated inversely with the majority of glycerolipids. Systolic blood pressure correlated positively with selected TG and DG species, but diastolic blood pressure did not correlate with any plasma lipid. Of the sphingolipids, dhCer C18:0 and all saturated Cer correlated positively with visceral fat and some
Lipidomics in Insulin Resistance and Obesity

positively with FGF-21 and inversely with adiponectin. Plasmalogen species correlated inversely with adiposity, liver fat and insulin. In muscle (Supporting Information, Figure 1B), the majority of TG correlated positively with subcutaneous fat and some correlated positively with insulin and inversely with ARQ. Of the sphingolipids, Cer C18:0 correlated positively with visceral and liver fat, and with systolic and diastolic blood pressure, and inversely with ARQ. Similar relationships were demonstrated between metabolic factors and muscle GM3 C18:0. Interestingly, muscle sphingolipids and glycerolipids did not correlate with the insulin signaling intermediates measured at any time point (not shown).

Gene expression

Lipid-related pathway analysis of muscle gene expression was performed in a representative subset (for gene array subcohort characteristics see Supporting Information, Table 2; for a comprehensive list of pathways that were significantly up- or downregulated between groups, see Supporting Information, Table 3). The sphingolipid metabolism and glycolysis/glucoseoneogenesis pathways were upregulated in OIR versus both OIS and Lean (Figure 3), suggesting that upregulation of these pathways characterize insulin resistance irrespective of obesity. Similarly, the steroid hormone biosynthesis pathway was downregulated in insulin resistance irrespective of obesity. On the other hand, oxidative phosphorylation was downregulated in both OIS and OIR compared with Lean, suggesting that downregulation of oxidative phosphorylation characterizes obesity per se. Similarly, the phosphatidylinositol signaling system was upregulated in obesity irrespective of insulin resistance. The ABC transporters pathway was downregulated in OIR versus Lean only (Figure 3). Fifty seven and 32 (out of 17,100) genes were significantly up- or downregulated between OIR and Lean and OIR and OIS, respectively (corrected \(P < 0.05\)). Interestingly, no genes were differentially regulated between OIS and Lean (corrected \(P > 0.05\)). Within the sphingolipid pathway, ceramide synthase (CERS)3 and CERS6 were 32 and 19% upregulated in OIR versus OIS, respectively and 24 and 15% in OIR versus Lean, respectively. Galactosylceramidase (GALC) was upregulated in OIR versus Lean (20%).

CERS1, the enzyme specific for C18:0 ceramide generation (22), was not mapped to the gene array.

Discussion

Lipidomic analysis of plasma and skeletal muscle revealed signatures of insulin resistance and overweight/obesity. The latter was only apparent in plasma and dominated by increases in TG and decreases in plasmalogen species. Conversely, insulin resistance was characterized in plasma by higher DG and CE and lower LPC species, while in muscle insulin resistance was predominantly associated with higher C18:0 sphingolipids.

This study identifies the long-chain C18:0 ceramide in muscle as a potential player in insulin resistance in humans. C18:0 ceramide is the most abundant ceramide in muscle in rodents (5,22) and equally most abundant with C24:0 ceramide in muscle in this study (~30% each). In mice, muscle C18:0 ceramide was the first and only ceramide to increase with 3-weeks of high fat feeding and induction of peripheral insulin resistance (5). In humans, other cross-sectional studies have reported increases in some (23,24) or all (25) saturated ceramides in insulin-resistant subjects with obesity. Coen and colleagues (8) have demonstrated higher concentrations of selected saturated ceramides, including C14:0, C16:0, and C18:0 in insulin-resistant versus insulin-sensitive postmenopausal women with obesity. In this study, ceramides other than C18:0 were not different between groups. In a small interventional study, Dube and colleagues reported decreases in different chain length ceramides with exercise and caloric restriction concomitant with improved insulin sensitivity, and while C18:0 ceramide decreased with exercise, its concentration was unchanged with caloric restriction (26). Similarly, decreases were noted in muscle C18:0 ceramide with bariatric surgery and exercise, but not with surgery alone, although both interventions improved insulin sensitivity; however, this may have been related to higher concentrations of C18:0 ceramide pre-exercise (27). These interventional studies demonstrate the complexity of the interactions between ceramides and insulin resistance in humans. Similarly, the role that muscle C16:0 ceramide plays in insulin resistance in humans is also unclear and findings from cross-sectional studies are conflicting. Some, similar to our findings, reported no difference between insulin-resistant and insulin-sensitive individuals (23,24), while others reported higher concentrations in insulin resistance (8). In any case, direct comparison between muscle lipidomic studies is complicated by different cohorts and different methodology. In all studies, including ours, cohort size was relatively small, resulting in greater variability and further complicating comparison between findings. In mice, however, C16:0 ceramide may be important in adipose tissue (5) and liver (4-6) insulin resistance. The role that individual ceramides play in insulin resistance is undergoing further research in animal models and the mechanisms by which different ceramide chain lengths and saturation induce insulin resistance await further study.

Accumulation of ceramides in tissues is determined by complex biosynthetic and degradative pathways. Numerous stimuli implicated in insulin resistance induce sphingolipid metabolism and determine ceramide metabolic fate. An inflammatory environment has been linked to upregulation of ceramides through toll-like receptor-4 activation that increases transcription of enzymes involved in de novo
ceramide synthesis, and pro-inflammatory cytokines can activate sphingomyelinase (28). Conversely, the adiponectin receptor is reported to have ceramidase activity (29) and FGF-21 is reported to stimulate adiponectin secretion while diminishing ceramide accumulation, thereby mediating insulin sensitizing effects in obese rodents (30). Here we report that the sphingolipid metabolism pathway was upregulated in muscle in insulin resistance independent of obesity. The most upregulated genes were genes encoding the de novo ceramide biosynthetic enzymes CERS3 and CERS6. While CERS3 may influence accumulation of the very long-chain ceramide C26 (22) not detected here, CERS6 generates C16 ceramides in liver and skeletal muscle (22), although we did not detect higher C16 ceramide in either plasma or muscle in insulin resistance. CERS1, the ceramide synthase with C18 fatty acid specificity in skeletal muscle (22), was not mapped. GALC, the gene encoding a lysosomal enzyme that hydrolyzes galactose ester bonds of higher order sphingolipids was upregulated in OIR and may explain increases in muscle ceramides.

While an adiponectin-FGF-21-ceramide axis has been proposed in animal models, correlations between these adipokines/hepatoxines and muscle Cer were not impressive. However, plasma C18:0 was the only ceramide correlating positively with circulating FGF-21 and inversely with adiponectin, further supporting a potential deleterious role for this ceramide in insulin resistance. Other than generation of other ceramides, C18:0 ceramide concentration in plasma and muscle as potential players in insulin resistance in obesity. Longitudinal studies. In this study, we identified C18:0 sphingolipids in tissues demonstrating mixed effects. Strengths of the study are the comprehensive lipidomics analysis of muscle and plasma in groups of individuals with equal excess adiposity diverging in insulin sensitivity and the inclusion of a lean insulin-sensitive reference group, a unique design enabling dissection of effects of insulin resistance from overweight/obesity. Limitations include the analysis of lipids in whole muscle, rather than in subcellular fractions, and the limited investigation of potential mediators of ceramide-induced insulin resistance in muscle. Lastly, lipidomics in fractionated lipoproteins was not performed and the association of specific lipoprotein lipids with insulin resistance and overweight/obesity awaits further study.

Insulin-sensitive or metabolically healthy individuals with obesity are suggested to be relatively protected from type 2 diabetes in longitudinal studies. In this study, we identified C18:0 sphingolipids in muscle as potential players in insulin resistance in obesity. Longitudinal studies are required to establish whether insulin sensitivity in obesity is sustained over time and whether it can be explained by unique tissue lipid signatures in humans. O

Acknowledgments

We thank A/Profs. Freund and Pocock, from the Nuclear Medicine Department, St. Vincent’s Hospital, Sydney, for DXA and CT analyses, Ms. Douglas, study nurse from the Garvan Institute, Dr. Jacqui Weir from Baker IDI Institute, Victoria, for assistance with mass spectrometry, and Drs. Ng and Miller, from the Garvan Institute, for performing the Western blot analyses in muscle lysates.

References

1. Samocha-Bonet D, Dixit VD, Kahn CR, et al. Metabolically healthy and unhealthy obese—the 2013 Stock Conference report. Obes Rev 2014;15:697-708.
2. Coen PM, Goodpaster BH. Role of intramyocellular lipids in human health. Trends Endocrinol Metab 2012;23:391-398.
3. Hannan YA, Obeid LM. Many ceramides. J Biol Chem 2011;286:27855-27862.
4. Raichur S, Wang ST, Chan PW, et al. CERS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab 2014;20:687-695.
5. Turner N, Kowalski GM, Leslie SJ, et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetesobesity 2013;56:1638-1646.

6. Turpin SM, Nicholls HT, Willmes DM, et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab 2014;20:678-686.

7. Bergman BC, Hunerdosse DM, Kereke A, et al. Localisation and composition of skeletal muscle diacylglycerol predicts insulin resistance in humans. Diabetologia 2012;55:1140-1150.

8. Coen PM, Dube JJ, Amati F, et al. Insulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content. Diabetes 2010;59:80-88.

9. Serlie MJ, Meijer AJ, Groener JE, et al. Short-term manipulation of plasma free fatty acids does not change skeletal muscle concentrations of ceramide and glucosylceramide in lean and overweight subjects. J Clin Endocrinol Metab 2007;92:1524-1529.

10. Skovbro M, Baranowski M, Skov-Jensen C, et al. Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity. Diabetologia 2008;51:1253-1260.

11. Meikle PJ, Christopher MJ. Lipidomics is providing new insight into the metabolic syndrome and its sequelae. Curr Opin Lipidol 2011;22:210-215.

12. Kulkarni H, Meikle PJ, Mamtani M, et al. Plasma lipidome is independently associated with variability in metabolic syndrome in Mexican American families. J Lipid Res 2014;55:939-946.

13. Meikle PJ, Wong G, Barlow CK, et al. Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. PLoS One 2013;8:e74341

14. Tonks KT, Ng Y, Miller S, et al. Impaired Akt phosphorylation in insulin-resistant human muscle is accompanied by selective and heterogeneous downstream defects. Diabetologia 2013;56:875-885.

15. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-264.

16. Gagnon-Bartsch JA, Speed TP. Using control genes to correct for unwanted variation in microarray data. Biostatistics (Oxford, England) 2012;13:539-552.

17. Kanehisa M, Goto S, Sato Y, et al. Data, information, knowledge and principle: from data to knowledge and principle in KEGG. Nucleic Acids Res 2014;42:D109-D205.

18. Eisenberg E, Levanon EY. Human housekeeping genes are compact. Trends Genet 2003;19:362-365.

19. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3

20. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34:287-293.

21. Heilbronn LK, Coster AC, Campbell LV, et al. The effect of short-term overfeeding on serum lipids in healthy humans. Obesity 2013;21:E649-E659.

22. Laviad EL, Albee L, Pankova-Kholmyansky I, et al. Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem 2008;283:5677-5684.

23. Thrush AB, Brindley DN, Chabowski A, et al. Skeletal muscle lipogenic protein expression is not different between lean and obese individuals: a potential factor in ceramide accumulation. J Clin Endocrinol Metab 2009;94:5053-5061.

24. Amati F, Dubé JJ, Carnero EA, et al. Skeletal-muscle triglycerides, diacylglycerols, and ceramides in insulin resistance. Diabetes 2011;60:2588-2597.

25. Adams JM, 2nd, Pratipanawatr T, Berria R, et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004;53:25-31.

26. Dubé JJ, Amati F, Toledo FG, et al. Effects of weight loss and exercise on insulin resistance, and intramyocellular triacylglycerol, diacylglycerol and ceramide. Diabetologia 2011;54:1147-1156.

27. Coen PM, Menshikova EV, Distefano G, Exercise and Weight Loss Improve Muscle Mitochondrial Respiration, Lipid Partitioning and Insulin Sensitivity Following Gastric Bypass Surgery. Diabetes 2015;64:3737-3750.

28. Holland WL, Bikman BT, Wang L-P, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid–induced ceramide biosynthesis in mice. J Clin Invest 2011;121:1858-1870.

29. Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramide activity initiates the pleiotropic actions of adiponectin. Nat Med 2011;17:55-63.

30. Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab 2013;17:790-797.

31. Boon J, Hoy AJ, Stark R, et al. Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance. Diabetes 2012;62:401-410.

32. Bergman BC, Brozinick JT, Strauss A, et al. Serum sphingolipid: relationships to insulin sensitivity and changes with exercise in humans. Am J Physiol Endocrinol Metab 2015;309:E398-E408.

33. Wiesener M, Leidl K, Boettcher A, Schmitz G, et al. Lipid profiling of PLPC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 2009;50:574-585.

34. Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolic approach. Diabetes 2013;62:639-648.

35. Lehmann R, Franken H, Dammeyer S, et al. Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care 2013;36:2331-2338.

36. Oresic M, Hyotylainen T, Kotronen A, et al. Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia 2013;56:2266-2274.

37. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007;46:1081-1090.

38. Anastassia CA, Kavouras SA, Lentzas Y, et al. Diabetes mellitus is associated with increased intramyocellular triglyceride, but not diglyceride, content in obese humans. Metabolism 2009;58:1636-1642.

39. Rhee EP, Cheng S, Larson MG, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 2011;121:1402-1411.
Author/s:
Tonks, KT; Coster, ACF; Christopher, MJ; Chaudhuri, R; Xu, A; Gagnon-Bartsch, J;
Chisholm, DJ; James, DE; Meikle, PJ; Greenfield, JR; Samocha-Bonet, D

Title:
Skeletal muscle and plasma lipidomic signatures of insulin resistance and overweight/obesity in humans

Date:
2016-04-01

Citation:
Tonks, K. T., Coster, A. C. F., Christopher, M. J., Chaudhuri, R., Xu, A., Gagnon-Bartsch, J.,
Chisholm, D. J., James, D. E., Meikle, P. J., Greenfield, J. R. & Samocha-Bonet, D. (2016).
Skeletal muscle and plasma lipidomic signatures of insulin resistance and overweight/obesity in humans. OBESITY, 24 (4), pp.908-916. https://doi.org/10.1002/oby.21448.

Persistent Link:
http://hdl.handle.net/11343/255780

File Description:
Published version

License:
CC BY